Tempest Therapeutics Reports Q3 2025 Financial Results

Tempest Therapeutics, Inc. ( (TPST) ) has released its Q3 earnings. Here is a breakdown of the information Tempest Therapeutics, Inc. presented to its investors.

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company based in Brisbane, California, focusing on developing targeted and immune-mediated therapeutics to combat cancer.

In its third-quarter 2025 earnings report, Tempest Therapeutics highlighted its ongoing strategic alternatives process aimed at maximizing shareholder value and announced the upcoming Phase 2 trial of TPST-1495 in collaboration with the National Cancer Institute.

The company reported a significant decrease in cash and cash equivalents, ending the quarter with $7.5 million compared to $30.3 million at the end of 2024. This decline was primarily due to operating activities, despite raising funds through direct and at-the-market offerings. Tempest also reported a reduced net loss of $3.5 million for the quarter, down from $10.6 million in the same period last year, attributed to decreased research and development expenses as the company re-prioritized its strategic focus.

Research and development expenses saw a notable reduction to $0.6 million from $7.6 million in the previous year, reflecting the company’s shift in focus. General and administrative expenses remained stable at $3.0 million. Year-to-date figures show a net loss of $22.2 million, improved from $28.0 million in 2024, with a continued emphasis on strategic realignment.

Looking ahead, Tempest Therapeutics remains committed to exploring strategic alternatives and advancing its clinical trials, with management expressing confidence in the potential impact of their therapeutics on cancer treatment. The company is poised to navigate the challenges of the biotechnology sector while seeking opportunities to enhance value for its stakeholders.